Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands.
Agonist
Cancer
Immunotherapy
Microenvironment
TLRs
Vaccine
Journal
BioImpacts : BI
ISSN: 2228-5652
Titre abrégé: Bioimpacts
Pays: Iran
ID NLM: 101558125
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
06
2021
revised:
29
11
2021
accepted:
04
12
2021
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
10
6
2022
Statut:
ppublish
Résumé
Immunotherapy is considered a promising approach for cancer treatment. An important strategy for cancer immunotherapy is the use of cancer vaccines, which have been widely used for cancer treatment. Despite the great potential of cancer vaccines for cancer treatment, their therapeutic effects in clinical settings have been limited. The main reason behind the lack of significant therapeutic outcomes for cancer vaccines is believed to be the immunosuppressive tumor microenvironment (TME). The TME counteracts the therapeutic effects of immunotherapy and provides a favorable environment for tumor growth and progression. Therefore, overcoming the immunosuppressive TME can potentially augment the therapeutic effects of cancer immunotherapy in general and therapeutic cancer vaccines in particular. Among the strategies developed for overcoming immunosuppression in TME, the use of toll-like receptor (TLR) agonists has been suggested as a promising approach to reverse immunosuppression. In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.
Identifiants
pubmed: 35677663
doi: 10.34172/bi.2022.23896
pmc: PMC9124882
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
261-290Références
Oncogene. 2014 Jul 3;33(27):3485-95
pubmed: 23934186
Immunol Cell Biol. 2008 Aug-Sep;86(6):506-14
pubmed: 18392040
Clin Cancer Res. 2007 Dec 1;13(23):7119-25
pubmed: 18056192
Oncologist. 2008 Aug;13(8):859-75
pubmed: 18701762
Mol Ther. 2013 Feb;21(2):348-57
pubmed: 23011032
Immunotherapy. 2014;6(10):1085-95
pubmed: 25428647
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Clin Cancer Res. 2018 Oct 15;24(20):4937-4948
pubmed: 29950349
J Immunother. 2006 Sep-Oct;29(5):558-68
pubmed: 16971811
Cancer Cell. 2007 Oct;12(4):300-1
pubmed: 17936555
Front Immunol. 2013 Dec 10;4:436
pubmed: 24339825
Biomaterials. 2020 Feb;230:119629
pubmed: 31767446
Small. 2019 Jan;15(4):e1803993
pubmed: 30569516
Int J Mol Sci. 2017 Feb 14;18(2):
pubmed: 28216575
Sci Rep. 2018 Sep 14;8(1):13812
pubmed: 30218032
Cancer Immunol Immunother. 2011 May;60(5):671-83
pubmed: 21327636
Oncol Lett. 2021 Feb;21(2):149
pubmed: 33552267
Int J Inflam. 2018 Mar 1;2018:2859135
pubmed: 29686833
J Immunol. 2004 Dec 15;173(12):7548-55
pubmed: 15585882
J Clin Invest. 2007 May;117(5):1184-94
pubmed: 17476348
J Exp Med. 2007 Jun 11;204(6):1441-51
pubmed: 17535975
Cancer Res. 1993 Nov 1;53(21):5176-80
pubmed: 8221654
Oncotarget. 2017 Jul 08;8(39):66656-66667
pubmed: 29029545
J Immunol. 2006 Apr 15;176(8):4894-901
pubmed: 16585585
Clin Cancer Res. 2019 Feb 15;25(4):1185-1195
pubmed: 30093453
BMC Cancer. 2013 Apr 02;13:172
pubmed: 23547558
Sci Rep. 2019 Mar 1;9(1):3299
pubmed: 30824859
J Exp Med. 2010 Nov 22;207(12):2675-87
pubmed: 21059856
J Immunother Cancer. 2016 Feb 16;4:6
pubmed: 26885368
J Am Acad Dermatol. 2010 Dec;63(6):975-83
pubmed: 20888065
Blood. 2015 Sep 17;126(12):1452-61
pubmed: 26228486
Mol Med Rep. 2015 Sep;12(3):3515-3520
pubmed: 26043701
Int J Dermatol. 2009 Mar;48(3):312-21
pubmed: 19261026
Clin Cancer Res. 2011 Mar 15;17(6):1603-15
pubmed: 21135147
Cancer Immunol Immunother. 2016 Oct;65(10):1201-12
pubmed: 27522582
J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24
pubmed: 24816725
Oncoimmunology. 2016 Sep 9;5(11):e1230578
pubmed: 27999739
Anticancer Res. 2016 Nov;36(11):5781-5792
pubmed: 27793900
Cancer Res. 2014 Nov 15;74(22):6430-40
pubmed: 25252912
PLoS One. 2010 Jun 07;5(6):e0010983
pubmed: 20539755
Oncotarget. 2015 Mar 10;6(7):4663-76
pubmed: 25609199
Sci Immunol. 2018 Jan 26;3(19):
pubmed: 29374079
J Cell Physiol. 2021 Jun;236(6):4121-4137
pubmed: 33230811
Nat Rev Immunol. 2003 Dec;3(12):984-93
pubmed: 14647480
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2066-71
pubmed: 22308357
Br J Cancer. 2010 Mar 30;102(7):1129-36
pubmed: 20234368
Sci Rep. 2019 Apr 11;9(1):5920
pubmed: 30976066
J Immunol. 2004 Apr 15;172(8):4733-43
pubmed: 15067049
J Immunother Cancer. 2019 Oct 16;7(1):260
pubmed: 31619293
Cancer Immunol Res. 2018 Nov;6(11):1364-1374
pubmed: 30201735
Cancer. 1985 Jan 15;55(2):357-62
pubmed: 2578083
Front Immunol. 2012 Apr 18;3:79
pubmed: 22566960
Clin Genitourin Cancer. 2009 Oct;7(3):E58-65
pubmed: 19815483
Cell Mol Immunol. 2010 Sep;7(5):381-8
pubmed: 20543857
Immunopharmacol Immunotoxicol. 2009 Jun;31(2):214-21
pubmed: 18798092
Vaccine. 2004 Jan 26;22(5-6):773-80
pubmed: 14741172
Arch Dermatol. 2003 Oct;139(10):1325-32
pubmed: 14568837
Eur J Cancer. 2015 Jan;51(2):146-56
pubmed: 25480557
Int J Mol Sci. 2020 Feb 20;21(4):
pubmed: 32093313
JCI Insight. 2021 Jun 22;6(12):
pubmed: 34032639
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
J Immunother Cancer. 2019 Jun 27;7(1):163
pubmed: 31248461
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
Eur J Pharmacol. 2007 Jun 1;563(1-3):1-17
pubmed: 17383632
Clin Cancer Res. 2011 Jun 15;17(12):3984-92
pubmed: 21543518
Arch Pharm Res. 2014;37(9):1234-40
pubmed: 24748512
J Clin Invest. 2005 Mar;115(3):739-46
pubmed: 15696196
J Clin Oncol. 2011 Jul 1;29(19):2667-74
pubmed: 21632509
Mol Ther. 2018 Mar 7;26(3):695-707
pubmed: 29433938
Ann Oncol. 2016 Aug;27(8):1492-504
pubmed: 27207108
Br J Dermatol. 2004 Sep;151(3):656-62
pubmed: 15377354
PLoS One. 2016 Jan 05;11(1):e0146372
pubmed: 26731269
Leuk Lymphoma. 2012 Feb;53(2):211-7
pubmed: 21812536
Pharmacol Rev. 2009 Jun;61(2):177-97
pubmed: 19474110
Nat Commun. 2019 Oct 15;10(1):4682
pubmed: 31615993
Biotechnol Adv. 2012 Jan-Feb;30(1):251-60
pubmed: 21664961
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Drug Discov Today. 2014 Apr;19(4):379-82
pubmed: 24012797
Sci Rep. 2019 Jun 12;9(1):8572
pubmed: 31189943
Cell Mol Immunol. 2018 May;15(5):428-437
pubmed: 29553135
Cancer Immunol Res. 2015 Mar;3(3):278-287
pubmed: 25633712
Eur J Cancer. 2017 Mar;73:30-37
pubmed: 28142059
Mol Med Rep. 2013 Oct;8(4):1074-8
pubmed: 23982165
J Biomed Mater Res A. 2007 Jun 1;81(3):652-62
pubmed: 17187395
J Biol Chem. 1982 Oct 10;257(19):11808-15
pubmed: 6749846
Int J Cancer. 2014 Aug 15;135(4):820-9
pubmed: 24390981
Eur J Immunol. 2012 Nov;42(11):3049-61
pubmed: 22806397
Cancer Res. 2018 Sep 1;78(17):4943-4956
pubmed: 29945961
Int J Oncol. 2013 Jun;42(6):2087-93
pubmed: 23588478
Sci Transl Med. 2018 Jan 31;10(426):
pubmed: 29386357
Crit Rev Oncol Hematol. 2015 Apr;94(1):31-44
pubmed: 25577571
Cell Mol Immunol. 2014 Mar;11(2):150-9
pubmed: 24362470
J Immunother. 2008 Jun;31(5):520-7
pubmed: 18463532
Clin Cancer Res. 2012 Dec 1;18(23):6497-508
pubmed: 23032745
Int J Dermatol. 2005 Jan;44(1):14-9
pubmed: 15663652
Cancer Immunol Immunother. 2015 Oct;64(10):1229-39
pubmed: 26091797
J Invest Dermatol. 2006 Jun;126(6):1338-47
pubmed: 16575388
Front Immunol. 2018 Jun 06;9:1188
pubmed: 29928275
Oncotarget. 2015 Oct 20;6(32):33781-90
pubmed: 26418952
Oncoimmunology. 2019 Sep 20;8(12):e1659096
pubmed: 31741757
Cancer Sci. 2018 Jul;109(7):2119-2129
pubmed: 29791768
Vaccine. 2008 Sep 15;26(39):5046-57
pubmed: 18680779
Front Immunol. 2014 Jul 25;5:328
pubmed: 25120541
Oncotarget. 2018 Jan 27;9(17):13301-13312
pubmed: 29568358
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Clin Cancer Res. 2012 Dec 15;18(24):6748-57
pubmed: 22767669
Immunol Lett. 2020 Jul;223:1-9
pubmed: 32311408
Oncotarget. 2016 Sep 13;7(37):59957-59964
pubmed: 27494867
J Cancer. 2017 Sep 15;8(16):3183-3189
pubmed: 29158790
Nat Immunol. 2008 Apr;9(4):361-8
pubmed: 18297073
Biomed Rep. 2018 Feb;8(2):126-132
pubmed: 29435270
Int Immunol. 2016 Jul;28(7):329-38
pubmed: 27006304
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
Immunotherapy. 2009 Nov;1(6):949-64
pubmed: 20563267
Biomed Pharmacother. 2019 Apr;112:108657
pubmed: 30798119
Cancer Immunol Res. 2018 Aug;6(8):930-940
pubmed: 30021725
Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12
pubmed: 18262679
Expert Rev Anti Infect Ther. 2011 Feb;9(2):261-9
pubmed: 21342073
Sci Rep. 2017 May 10;7(1):1663
pubmed: 28490734
Oncol Lett. 2017 Jul;14(1):1162-1166
pubmed: 28693290
Ann Diagn Pathol. 2015 Aug;19(4):232-8
pubmed: 26071054
Cancer Immunol Immunother. 2015 Apr;64(4):429-36
pubmed: 25567751
J Dermatol Sci. 2016 Mar;81(3):182-91
pubmed: 26775629
Precis Clin Med. 2018 Sep;1(2):65-74
pubmed: 30687562
Nat Commun. 2017 Nov 17;8(1):1592
pubmed: 29150602
Oncogene. 2008 Jan 7;27(2):161-7
pubmed: 18176597
Clin Cancer Res. 2017 Oct 1;23(19):5679-5686
pubmed: 28972083
Acta Naturae. 2010 Jul;2(3):21-9
pubmed: 22649649
Am J Reprod Immunol. 2007 Feb;57(2):93-107
pubmed: 17217363
Oncoimmunology. 2012 Mar 1;1(2):227-228
pubmed: 22720251
Oncotarget. 2014 Mar 15;5(5):1363-81
pubmed: 24658058
Oncotarget. 2017 Apr 11;8(15):24932-24948
pubmed: 28212561
J Hematol Oncol. 2017 Apr 7;10(1):82
pubmed: 28388966
Ann Oncol. 2018 Oct 1;29(10):2076-2084
pubmed: 30137193
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):27-37
pubmed: 32339645
Cancer Microenviron. 2009 Sep;2 Suppl 1:205-14
pubmed: 19685283
Clin Cancer Res. 2012 Dec 15;18(24):6668-78
pubmed: 23048078
Oncol Res. 2012;20(1):15-24
pubmed: 23035361
PLoS One. 2014 Aug 07;9(8):e104351
pubmed: 25102137
Eur J Immunol. 2012 Jan;42(1):101-9
pubmed: 22002164
Sci Rep. 2016 Dec 21;6:39598
pubmed: 28000738
EBioMedicine. 2019 Jul;45:328-340
pubmed: 31300344
Cancer Immun. 2004 Sep 23;4:9
pubmed: 15384929
J Immunol. 2004 Mar 1;172(5):2739-43
pubmed: 14978071
Neuro Oncol. 2006 Jan;8(1):60-6
pubmed: 16443949
Front Immunol. 2019 Oct 22;10:2388
pubmed: 31695691
Cancer Res. 1992 Jun 1;52(11):3005-10
pubmed: 1591717
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
NPJ Vaccines. 2020 Jun 16;5(1):50
pubmed: 32579133
J Invest Dermatol. 2000 Jan;114(1):135-41
pubmed: 10620129
Immunooncol Technol. 2019 Oct 16;3:15-23
pubmed: 35757301
Methods Mol Biol. 2007;380:457-68
pubmed: 17876112
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10453-10462
pubmed: 31076558
Ann Oncol. 2012 Jan;23(1):72-77
pubmed: 21464154
Front Immunol. 2014 Jul 10;5:316
pubmed: 25071777
Clin Cancer Res. 2008 Feb 1;14(3):856-64
pubmed: 18245549
Immunol Cell Biol. 2018 Apr;96(4):390-400
pubmed: 29344995
Int J Cancer. 2014 Jun 1;134(11):2633-45
pubmed: 24443321
Target Oncol. 2018 Oct;13(5):583-598
pubmed: 30229471
Cancer Discov. 2018 Oct;8(10):1250-1257
pubmed: 30154193
Br J Dermatol. 2004 Apr;150(4):761-7
pubmed: 15099376
Cell Rep. 2017 May 30;19(9):1874-1887
pubmed: 28564605
Front Immunol. 2019 Mar 20;10:503
pubmed: 30949170
Adv Drug Deliv Rev. 2019 Jul;147:37-43
pubmed: 31302192
Immunology. 2015 Apr;144(4):621-30
pubmed: 25322876
Mol Pharm. 2018 Nov 5;15(11):4777-4800
pubmed: 30226786
Theranostics. 2020 Feb 10;10(7):3099-3117
pubmed: 32194857
Expert Rev Vaccines. 2003 Apr;2(2):219-29
pubmed: 12899573
J Invest Dermatol. 2009 Nov;129(11):2676-85
pubmed: 19516264
Leukemia. 2017 Jul;31(7):1611-1621
pubmed: 27890931
Clin Dev Immunol. 2011;2011:609579
pubmed: 22110526
J Drugs Dermatol. 2005 Nov-Dec;4(6):708-17
pubmed: 16302556
Sci Rep. 2015 Dec 03;5:17622
pubmed: 26631690
J Immunol Res. 2021 May 22;2021:9912188
pubmed: 34124272
J Immunother Cancer. 2019 Sep 11;7(1):244
pubmed: 31511088
Cancer Discov. 2018 Oct;8(10):1258-1269
pubmed: 30154192
Oncotarget. 2015 Sep 29;6(29):27252-66
pubmed: 26287667
Oncogene. 2008 Jan 7;27(2):190-9
pubmed: 18176600
Front Immunol. 2019 Jan 22;10:8
pubmed: 30723469
J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49
pubmed: 12902443
J Clin Oncol. 2010 Oct 1;28(28):4324-32
pubmed: 20697067
J Immunol. 2008 Jul 1;181(1):776-84
pubmed: 18566444
Clin Cancer Res. 2007 May 15;13(10):2961-9
pubmed: 17504997
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
PLoS One. 2016 Dec 2;11(12):e0167057
pubmed: 27911948
Cancer Immunol Res. 2014 Aug;2(8):720-4
pubmed: 24801836
Br J Dermatol. 2003 Nov;149 Suppl 66:59-61
pubmed: 14616354
J Immunol. 2004 Jun 1;172(11):6922-30
pubmed: 15153511
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Mol Cancer Ther. 2017 Jun;16(6):1068-1079
pubmed: 28138030
Cancer Res. 1985 Nov;45(11 Pt 2):5904-9
pubmed: 2414002
Mol Immunol. 2007 Apr;44(11):2850-9
pubmed: 17328955
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Antimicrob Agents Chemother. 2005 Oct;49(10):3991-6
pubmed: 16189071
Mol Cancer. 2020 Jul 17;19(1):116
pubmed: 32680511
Front Immunol. 2017 Dec 21;8:1897
pubmed: 29312355
Leukemia. 2010 Jan;24(1):222-6
pubmed: 19759558
Cancer Immunol Immunother. 2019 Jul;68(7):1211-1222
pubmed: 31069460
Cancer Lett. 2016 Jan 1;370(1):85-90
pubmed: 26477683
J Clin Oncol. 2006 Dec 20;24(36):5716-24
pubmed: 17179105
Oncoimmunology. 2013 Apr 1;2(4):e23493
pubmed: 23734310
Clin Cancer Res. 2007 Oct 15;13(20):6168-74
pubmed: 17947483
Front Immunol. 2019 May 29;10:1144
pubmed: 31191528
Cancer Metastasis Rev. 2011 Mar;30(1):13-25
pubmed: 21271351
Int Immunopharmacol. 2007 Nov;7(11):1471-82
pubmed: 17761351
Cancer Immunol Res. 2020 Jan;8(1):70-80
pubmed: 31699709
Front Pharmacol. 2017 May 31;8:304
pubmed: 28620298
Int J Oncol. 2018 Sep;53(3):1193-1203
pubmed: 29956749
Oncol Rep. 2016 Feb;35(2):793-800
pubmed: 26718332